Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin- 2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent
주제(키워드)
2 dipropylamino 8 hydroxy 1 methyltetralin
, alkyl group
, alpha smooth muscle actin
, antifibrotic agent
, aspartate aminotransferase
, cisapride
, collagen type 1
, cytochrome P450 2C19
, cytochrome P450 2C9
, cytochrome P450 2D6
, immunomodulating agent
, n ((4 ([1
, 2
, 4]triazolo[1
, 5 a]pyridin 6 yl) 5 (6 methylpyridin 2 yl) 1h imidazol 2 yl)methyl) 2 fluoroaniline
, n ((4 ([1
, 2
, 4]triazolo[1
, 5 a]pyridin 6 yl) 5 (6 methylpyridin 2 yl) 1h imidazol 2 yl)methyl)aniline
, protein kinase
, Smad2 protein
, Smad3 protein
, Smad4 protein
, transforming growth factor beta type 1 receptor kinase inhibitor
, transforming growth factor beta1
, unclassified drug
, vasculotropin receptor 1
, vasculotropin receptor 2
, vasculotropin receptor 3
, animal cell
, animal experiment
, animal model
, area under the curve
, article
, controlled study
, drug bioavailability
, drug exposure
, drug synthesis
, human
, human cell
, IC 50
, liver fibrosis
, liver microsome
, maximum plasma concentration
, mouse
, nonhuman
, protein expression
, protein phosphorylation
등재
SCIE, SCOPUS
발행기관
American Chemical Society
발행년도
2014
총서유형
Journal
URI
http://www.dcollection.net/handler/ewha/000000096213
본문언어
영어
Published As
http://dx.doi.org/10.1021/jm500115w
LOADING...
